CTC expressing both epithelial and mesenchymal markers, have been identified in patients with breast and non-small cell lung cancer [25] suggesting that CTC may undergo an epithelial to mesenchymal transition (EMT) and thus exhibit reduced expression of epithelial markers such EpCAM and CK. The gene discussed is EPCAM; the disease is non-small cell lung carcinoma.